All News #Library
Sciences
Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab
17 Dec 2020 //
BUSINESSWIRE
National Institutes of Health Selects Humanigen’s Lenzilumab for its COVID-19
27 Jul 2020 //
BUSINESSWIRE
Humanigen Reports Additional Analysis of Lenzilumab in Severe Critical COVID-19
16 Jun 2020 //
BUSINESSWIRE

Market Place
Sourcing Support